Work

Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial

Year: 2025
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Prolonged lipid-lowering therapy has demonstrated its ability to induce plaque regression and improve the plaque morphology of mild atherosclerotic lesions. AIMS: This trial aimed to assess the short-term effect of evolocumab in addition to high-intensity statin therapy (HIST) on relevant non-culprit coronary artery lesions using fractional flow reserve (FFR) measurements and multimodality intracoronary imaging. METHODS: ). The secondary endpoints were the differences in the change in IVUS-derived atheroma volume parameters. RESULTS: was -27.8 (95% CI: -72.2 to 16.6) for evolocumab-treated patients versus -35.6 (95% CI: -82.5 to 11.4) for placebo-treated patients (adjusted mean difference: 7.8, 95% CI: -40.9 to 56.4; p=0.8). No between-group differences in any IVUS-derived parameter were found. CONCLUSIONS: . (ClinicalTrials.gov: NCT04141579).
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: green
OpenAlex ID: W4413220771
FWCI: 9.554
Cites: 28
Cited by: 11
Related to: 10